Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Privia Health (PRVA) delivered earnings and revenue surprises of -12.50% and +8.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.